Navigation Links
APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
Date:2/24/2010

Leading medical centers in North America participate in study to evaluate the safety and efficacy of cyclosporine inhalation solution in preventing chronic rejection in lung transplant recipients.

Burlingame, CA (PRWEB) February 24, 2010 -- APT Pharmaceuticals, a specialty drug development company focused on the development of inhaled cyclosporine, announced today that it has completed enrollment in its Phase III CYCLIST trial. The multi-center, randomized, controlled study enrolled 288 recent lung transplant recipients across 19 leading centers in North America, including the Cleveland Clinic; the University of Pittsburgh; and the University of California, San Francisco.

The objective of the CYCLIST trial is to evaluate the safety and efficacy of cyclosporine inhalation solution in improving bronchiolitis obliterans syndrome (BOS)-free survival following lung transplantation. Lung transplantation is a life-saving procedure for people with end-stage lung diseases who have exhausted all other available treatment options. However, average survival post-lung transplant is less than five years -- significantly less than all other forms of solid organ transplant. Poor long-term outcomes in lung transplant patients appear to relate to BOS, a manifestation of chronic rejection, which remains a persistent problem despite administration of multi-drug systemic immunosuppressive regimens.

"We appreciate the broad support provided by the community of lung transplant centers, advocacy groups, patients and caregivers," said Dr. Charlie Johnson, chief medical officer of APT Pharmaceuticals. "They have exceeded our expectations by enrolling this trial in just over a year."

About Cyclosporine Inhalation Solution

Cyclosporine Inhalation Solution (CIS) is an inhaled formulation of cyclosporine A, an oral medication that has been widely used for over 25 years to prevent rejection in solid organ transplant recipients. Preliminary clinical studies of CIS in lung transplant recipients have been conducted, including a placebo-controlled study that was published as the lead article in the New England Journal of Medicine in January 2006 (Iacono et al 2006). This small, single-center, randomized, controlled, Phase II study showed that administration of inhaled cyclosporine, initiated soon after transplantation, reduced chronic rejection and improved survival while not increasing the risk of infection. This study led to the multi-center, APT Phase III CYCLIST study.

About APT Pharmaceuticals, Inc.

APT Pharmaceuticals, Inc. is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection. APT is preparing for study data and commercialization of the product in the US and Europe. Leading life sciences investors Charter Life Sciences, Great Point Partners, InterWest Partners, Pinnacle Ventures, Research Corporation Technologies, Three Arch Partners, Versant Ventures and Vivo Ventures back APT.

Disclaimer

Cyclosporine Inhalation Solution (CIS) is an investigational drug and is not currently approved by the FDA.

For more information about APT, please visit www.aptbio.com.

For more information about the CYCLIST trial, please visit www.cycliststudy.com.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3634594.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):